Comparison of two dosing regimens of cisapride in the treatment of reflux oesophagitis

Alimentary Pharmacology and Therapeutics

Volumn 11, Issue 3, 1997, Pages 497-503

  Schutze K ^a   Bigard, M A ^b   Van Waes, L ^c   Hinojosa, J ^d   Bedogni, G ^e   Hentschel, E ^a  

^a HANUSCH HOSPITAL   (Austria)

^b CHU NANCY BRABOIS   (France)

^c Algemeen Stedelijk Ziekenhuis   (Belgium)

^d Gastroenterology Service   (Spain)

^e Servizio di Endoscopia Digestiva   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; CISAPRIDE; PLACEBO;

ADULT; AGED; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENDOSCOPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; TABLET;

EID: 0030750193     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1997.00180.x     Document Type: Article

References (12)

1. McCallum RW, Prakosh C, Campoli-Richards DH, Goa KL. Cisapride: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use as a prokinetic agent in gastrointestinal motility disorders. Drugs 1988; 36: 652-81.
2. Baldi F, Bianchi-Porro C, Dobrilla G, et al. Cisapride versus placebo in reflux esophagitis. A multicentre double-blind trial. J Clin Gastroenterol 1988; 10: 614-8.
3. Verlinden M. Review article: a role for gastrointestinal prokinetic agents in the treatment of reflux oesophagitis? Aliment Pharmacol Ther 1989; 3: 113-31.
4. Savary M, Miller G, Der Ösophagus. Solothurn: Verlag Gassmann, 1977.
5. Blum AL, Adami B, Bouzo MH, et al. Effect of cisapride on relapse of esophagitis. A multinational placebo-controlled trial in patients healed with an antisecretory drug. Digest Dis Sci 1993; 38(3): 551-60.
6. Blackwelder WC. "Proving the null hypothesis" in clinical trials. Control Clin Trials 1982; 3: 345-53.
7. Richter JE. A critical review of current medical therapy for gastroesophageal reflux disease. J Clin Gastroenterol 1986; 8(Suppl. 1): 72-80.
8. McCallum RW and the ACG Committee on PDA-related Matters. GI drug column: Cisapride: A new class of prokinetic agent. Am J Gastroenterol 1991; 86: 135-49.
9. Van Peer A, Embrechts L, Woestenborghs R. Pharmacokinetics of R 51 619 and its bioavailability after oral and rectal administration in six healthy, male volunteers. Clinical Research Report R 51 619/3, 1982 (N 30670).
10. Van de Velde V, Verlinden M. Woestenborghs R, Van Peer A, Mesens J, Heykants J. Cisapride bioavailability after a 20 mg tablet. Clinical Research Report R 51 619/122, 1988 (N59956).
11. Gilbert RJ, Dodds WJ, Kahribas PJ, Hogan WJ, Lipman S. Effect of cisapride, a new prokinetic agent, on oesophageal motor function. Digest Dis Sci 1987; 32: 1331-6.
12. Geldof H, Hazelhoff B, Otten MH and the Dutch cisapride trialists. Two different dose regimens of cisapride in the treatment of reflux esophagitis. A double-blind comparison with ranitidine. Aliment Pharmacol Ther 1993; 7: 409-15.